Rigel Pharmaceuticals | RIGL - Assets


Rigel Pharmaceuticals reported $242.53M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 226.8M 7.09M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Anika Therapeutics USD 190.27M 833K Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Celldex Therapeutics USD 582.98M 65.46M Dec/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Veracyte USD 1.41B 38.23M Dec/2025